Similar articles

• A comparative study of a new drug MK 185 with clofibrate in the treatment of hyperlipidaemias.

  Jepson EM, Small E, Grayson MF, Bance G, Billimoria JD. Jepson EM, et al. Atherosclerosis. 1972 Jul-Aug;16(1):9-14. doi: 10.1016/0021-9150(72)90003-2. Atherosclerosis. 1972. PMID: 4341723 Clinical Trial. No abstract available.
• The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.

  Arnold A, McAuliff JP, Powers LG, Phillips DK, Beyler AL. Arnold A, et al. Atherosclerosis. 1979 Feb;32(2):155-63. doi: 10.1016/0021-9150(79)90080-7. Atherosclerosis. 1979. PMID: 454514
• [New derivatives of clofibrate and probucol. Preliminary study of their hypolipemic activity].

  de Meglio P, Ravenna F, Manzardo S, Gentili P, Riva M. de Meglio P, et al. Farmaco Sci. 1985 Nov;40(11):833-44. Farmaco Sci. 1985. PMID: 4085644 Italian.
• Newer hypolipidemic compounds.

  Kritchevsky D. Kritchevsky D. Adv Exp Med Biol. 1975;63:135-50. doi: 10.1007/978-1-4684-3258-9_9. Adv Exp Med Biol. 1975. PMID: 1106139 Review. No abstract available.
• Hypolipidemic drugs.

  Sirtori C, Fumagalli R, Paoletti R. Sirtori C, et al. Adv Exp Med Biol. 1973;38:171-98. Adv Exp Med Biol. 1973. PMID: 4594063 Review. No abstract available.